Profile image
Story Views

Last Hour:
Last 24 Hours:

Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2016

Tuesday, February 7, 2017 3:34
% of readers think this story is Fact. Add your two cents.

Dry (Atrophic) Macular Degeneration therapeutics industry report provides comprehensive information on the therapeutics under development for Dry (Atrophic) Macular Degeneration, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dry (Atrophic) Macular Degeneration and features dormant and discontinued projects.


Dry atrophic macular degeneration is generally characterized by a slow but progressive visual loss. This is characterized by yellow spots under the retina, called drusen, which are accumulations of metabolic waste products. Symptoms include blurred or decreased central close-up and distance vision, blind spots, micropsia and straight lines look distorted. Predisposing factors include age and family history.

Browse more detail information about Dry (Atrophic) Macular Degeneration market report at:

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Key players in Dry (Atrophic) Macular Degeneration – Pipeline Review, H2 2016:

  • Aciont Inc.
  • Alimera Sciences, Inc.
  • Allergan Plc
  • Apellis Pharmaceuticals Inc
  • Astellas Pharma Inc.
  • Benitec Biopharma Limited
  • Biophytis SAS
  • Catalyst Biosciences, Inc.
  • Cell Cure Neurosciences, Ltd.
  • Charlesson LLC.
  • Foamix Pharmaceuticals Ltd.

Get a PDF Sample of Dry (Atrophic) Macular Degeneration Market Research Report at:

Drug Profiles of Included in Dry (Atrophic) Macular Degeneration Therapeutics Development Market Report

  • A-005
  • APL-2
  • BBAMD-231
  • BIO-201
  • brimonidine tartrate implant

And other drug profiles
Have any query? ask our expert @

Key Topics Covered:
2.Dry (Atrophic) Macular Degeneration Overview
3.Dry (Atrophic) Macular Degeneration Therapeutics Development
4.Pipeline Products for Dry (Atrophic) Macular Degeneration – Overview
5.Pipeline Products for Dry (Atrophic) Macular Degeneration – Comparative Analysis
6.Dry (Atrophic) Macular Degeneration – Therapeutics under Development by Companies
7.Dry (Atrophic) Macular Degeneration – Therapeutics under Investigation by Universities/Institutes
8.Dry (Atrophic) Macular Degeneration Products Glance
9.Late Stage Products
10.Clinical Stage Products
11.Early Stage Products
12.Dry (Atrophic) Macular Degeneration – Products under Development by Companies
13.Dry (Atrophic) Macular Degeneration – Products under Investigation by Universities/Institutes
14.Dry (Atrophic) Macular Degeneration – Companies Involved in Therapeutics Development
15.Dry (Atrophic) Macular Degeneration Drug Profiles
16.Dry (Atrophic) Macular Degeneration Dormant Projects
17.Dry (Atrophic) Macular Degeneration Discontinued Products
18.Dry (Atrophic) Macular Degeneration Featured News & Press Releases
And Continue…

Get Discount on Dry (Atrophic) Macular Degeneration Market Research Report at:

This research study help to:
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Dry (Atrophic) Macular Degeneration
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Dry (Atrophic) Macular Degeneration pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


About Absolute Report:

Absolute Reports is an upscale platform to help key personnel in the business world in strategizing and taking visionary decisions based on facts and figures derived from in depth market research. We are one of the top report resellers in the market, dedicated towards bringing you an ingenious concoction of data parameters.


Mr. Ameya Pingaley

Absolute Reports

+1-408 520 9750

Email –


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.